Halothane
Halothane, sold under the brand name Fluothane among others, is a general anaesthetic. It can be used to induce or maintain anaesthesia. One of its benefits is that it does not increase the production of saliva, which can be particularly useful in those who are difficult to intubate. It is given by inhalation.
Clinical data | |
---|---|
Trade names | Fluothane |
AHFS/Drugs.com | FDA Professional Drug Information |
License data | |
Routes of administration | Inhalation |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Metabolism | Hepatic (CYP2E1) |
Excretion | Kidney, respiratory |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.005.270 |
Chemical and physical data | |
Formula | C2HBrClF3 |
Molar mass | 197.38 g·mol−1 |
3D model (JSmol) | |
Density | 1.871 g/cm3 (at 20 °C) |
Melting point | −118 °C (−180 °F) |
Boiling point | 50.2 °C (122.4 °F) |
| |
| |
(verify) |
Side effects include an irregular heartbeat, respiratory depression, and hepatotoxicity. Like all volatile anesthetics, it should not be used in people with a personal or family history of malignant hyperthermia. It appears to be safe in porphyria. It is unclear whether its usage during pregnancy is harmful to the fetus, and its use during a C-section is generally discouraged. Halothane is a chiral molecule that is used as a racemic mixture.
Halothane was discovered in 1951. It was approved for medical use in the United States in 1958. It is on the World Health Organization's List of Essential Medicines. Its use in developed countries has been mostly replaced by newer anesthetic agents such as sevoflurane. It is no longer commercially available in the United States. Halothane also contributes to ozone depletion.